invivodata Opens Registration for Annual Patient Reported Outcomes Conference

Programs for PRO Educational Initiative are Announced

PITTSBURGH — invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today officially opened registration for ePROficiency™ 2009 – it’s annual Patient Reported Outcomes Conference. Pharmaceutical research professionals can visit http://www.invivodata.com/epro2009 to register for the educational conference, which is being held April 21 – April 23, 2009 in Naples, Florida.

Gathering scientists, technologists, and regulatory experts, this annual conference produces interactive discussions on PRO regulatory guidelines and best practices for designing and executing ePRO systems in clinical research. This year’s agenda includes speakers from regulatory agencies and top pharmaceutical companies, including Bristol-Myers Squibb, Cypress Bioscience, Grünenthal, and Hoffmann-La Roche. Attendees can participate in presentations and case studies on topics ranging from the successful development of a PRO strategy to eDiary supported Food and Drug Administration (FDA) submissions.

Representatives from 30 international biopharmaceutical companies attended last year’s conference to engage in discussions about the advancing role of ePRO in new drug development. A senior director of clinical science at Takeda© Pharmaceuticals who attended last year’s event remarked, “Don’t think about embarking on an ePRO strategy for your drug development without attending this conference – a must attend event.”

ePROficiency is the cornerstone of invivodata’s ongoing educational initiative which is designed to benefit all clinical researchers interested in ePRO, regardless of their experience or knowledge of the current PRO environment. invivodata offers a variety of programs that focus on recent regulatory and industry trends related to PROs, including:

ePRO Resource Center (http://www.invivodata.com/epro-resources). Current regulatory, scientific, and industry publications on PROs in clinical research are available on invivodata’s ePRO Resource Center. Here, clinical researchers can find relevant and practical information, including a recently published White Paper which answers common questions about the FDA’s Draft Guidance on Patient Reported Outcomes.
ePRO Pulse™ e-mail newsletter. This quarterly newsletter sheds light on the latest developments in ePRO research and answers common questions about evolving ePRO regulations. To sign-up, visit http://www.invivodata.com/epro-resources/epro-pulse-newsletter/
Webinars. invivodata will continue its popular Web seminar series in 2009, and has extended this program by offering complimentary access to recordings of previously conducted Webinars via its ePRO Resource Center (http://www.invivodata.com/epro-resources/presentations-podcasts).

“The feedback we have received on the relevance and effectiveness of the ePROficiency programs has been very positive,” said Tom Henson, vice president of marketing at invivodata. “We’re pleased to once again host this international conference and to continue offering programs that provide answers to many of the questions clinical trial sponsors have about effectively using ePRO in clinical development.”

Additional information and registration for any of invivodata’s 2009 educational programs can be found at www.invivodata.com.

About invivodata inc.
invivodata combines behavioral science, information technology, and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata’s electronic Patient Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata’s solutions include comprehensive trial-support services that facilitate the collection of ePRO data, web-based access to study data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consulting on the use of PRO data in a regulated environment. invivodata’s solution has been used in more than 275 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information visit www.invivodata.com.

RSS Feed